Google shuts down AlphaFold, undermining its own AI-cures-cancer pitch

The shutdown of AlphaFold marks a striking reversal in how Google has publicly positioned its AI investments. For years, Alphabet President Ruth Porat claimed the company could 'cure cancer in our lifetime' thanks to AI, and Demis Hassabis suggested in a 2024 60 Minutes interview that 'we can cure all disease with the help of AI.' These claims were part of a broader narrative by Big Tech executives—including OpenAI's Dario Amodei and Sam Altman—that the massive human, environmental, and financial costs of the AI boom are justified by immense humanitarian benefits. AlphaFold stood as perhaps the only concrete data point supporting that narrative: a genuine scientific breakthrough with potential applications in cancer research and other diseases.

The real reason for the shutdown, as detailed in the Financial Times reporting, reveals a different priority. Google's frustration with Hassabis centered not on the quality of his work but on his insistence that AlphaFold remain freely available to the scientific community. That decision, while advancing human knowledge, eliminated any path to commercial monopoly or return on investment. Alphabet is spending $200 billion in 2026 alone on AI infrastructure, and AlphaFold—precisely because it was a genuine scientific tool rather than a proprietary business asset—could not help recoup that spending. The calculation was brutally straightforward: a project that serves humanity but not shareholders could not survive.